

Ryah Medtech Inc

09:30 05 Dec 2019

RYAH Medtech's dose-measuring inhaler passes milestone safety test

RYAH Medtech Inc revealed Thursday that the company's dose-measuring dry herb inhaler has passed key medical device compliance tests.

In a statement, the privately-owned New York-based company said it cleared the CE-RED NB and IEC 60601 medical device safety tests, which constitute technical standards for the safety and performance of medical electrical equipment, published by the International Electrotechnical Commission.

RYAH Medtech said it is a widely accepted benchmark and compliance with IEC60601 has become a requirement for the commercialization of electrical medical equipment in many countries.

READ: RYAH Medtech data finds 78% of male medical cannabis patients use cannabis daily or near-daily, start treatment earlier in life

"RYAH's distinct objective is to provide the most comfortable and secure experience for patients utilizing plant-based treatment options. The completion of the IEC 60601 device safety test directive marks a new milestone for RYAH and reconfirms our intention to architect the highest quality delivery solutions for plant-based medicine," said RYAH Medtech CEO Gregory Wagner.

"As we continue to focus on transforming patient care with accurate data analytics and perfecting our safety model, countries around the world are quickly and permanently reshaping their understanding of plant-based medicine: they tend to only embrace the devices which meet and exceed stringent safety standards," he added.

The RYAH Medtech boss noted that completing the safety test enabled the company to initiate global medical registration applications while RYAH continued to move forward towards its Canadian Securities Exchange listing.

Designed to give patients control, the RYAH inhaler measures inhalations to deliver precise and predictable results. It connects to a mobile app with features like stat-tracking and pre-sets for temperature and dosage that are customized to individual needs.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Share Information

Code: RYAH
Listing: PRIVATE-NA
Sector: Cannabis
Website: us.ryah.com

Company Synopsis:

*RYAH is the first vaporizer that lets users track and control how much they inhale, ensuring consistent, predictable results. It offers accurate temperature and dosing control down to the millileter. *

*The device tracks the effects of each session and uses artificial intelligence to help select the best strain of cannabis for any patient's symptoms. *

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Ryah Medtech Inc named herein, including the promotion by the Company of Ryah Medtech Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).